US Capitol Capsule: SCOTUS not ACA cure-all: drug access remains problematic
This article was originally published in Scrip
Executive Summary
Even though the US Supreme Court last week upheld the tax credit subsidies provision of the Affordable Care Act (ACA), ensuring eligible Americans who enrolled in plans operated by the federal government could keep the benefit, making it more likely they will be able to afford their coverage – and in so doing, ensuring biopharmaceutical makers and others in the healthcare sector retain their millions of new customers – there remains some barriers preventing access to care, including to needed medicines, two large drug trade groups pointed out.